Neurocrine presents two-year Crenessity data

Neurocrine (NBIX) Biosciences announced the presentation of new two-year data from the Phase 3 CAHtalyst Pediatric study demonstrating durable androgen control, sustained decreases in glucocorticoid doses and meaningful improvements in clinical outcomes associated with excess androgens and long-term GC exposure in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY. Consistent with these findings, patients with classic congenital adrenal hyperplasia continued to experience substantial reductions in adrenocorticotropic hormone and 17-hydroxyprogesterone while achieving lower, more physiologic GC doses. These data build upon previously reported one-year clinical outcomes results and were presented at the Pediatric Endocrine Society 2026 Annual Meeting in San Francisco. “These two-year findings showed that CRENESSITY achieved durable reductions in both androgen levels and glucocorticoid doses in children and adolescents with classic congenital adrenal hyperplasia, a population particularly vulnerable to the long-term health impact of excess hormone exposure during growth and development,” said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. “Improved hormonal control was associated with meaningful improvements in clinical outcomes, including body mass index and insulin resistance, supporting healthier outcomes as patients transition into adulthood.”